Anti–PD-L1 Treatment Induced Central Diabetes Insipidus

CONTEXT: Immune checkpoint inhibitors, including anti–programmed cell death protein 1 (PD-1), anti–programmed cell death protein ligand 1 (PD-L1), and anti–cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) monoclonal antibodies, have been widely used in cancer treatment. They are known to cause immune-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Chen, Tella, Sri Harsha, Del Rivero, Jaydira, Kommalapati, Anuhya, Ebenuwa, Ifechukwude, Gulley, James, Strauss, Julius, Brownell, Isaac
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800826/
https://www.ncbi.nlm.nih.gov/pubmed/29220526
http://dx.doi.org/10.1210/jc.2017-01905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800826/
https://www.ncbi.nlm.nih.gov/pubmed/29220526
http://dx.doi.org/10.1210/jc.2017-01905

Ejemplares similares